
    
      The POISE-3 pilot is a randomized controlled trial of 100 patients with, or at risk of,
      atherosclerotic disease who are undergoing noncardiac surgery. Utilizing a partial factorial
      design, the POISE-3 pilot will determine the effect of rosuvastatin versus placebo and TXA
      versus placebo in the perioperative setting.
    
  